文章：

展望未来：头颈部肿瘤的潜在诊疗一体化应用

A Look to the Future: Potential Theranostic Applications in Head and Neck Tumors

原文发布日期：19 February 2025

DOI: 10.3390/cancers17040695

类型: Article

开放获取: 是

英文摘要：

Theranostics, the practice of using a diagnostic radiopharmaceutical to guide radiotherapy with a chemically identical (or nearly identical) therapeutic radiopharmaceutical, is an exciting new field under development within the auspices of nuclear medicine. We aim to provide a narrative review of the areas of theranostics use and development which are occurring specifically in the head and neck, with attention to the therapeutic use of existing diagnostically used radiotracers such as agents that target prostate-specific membrane antigen (PSMA) and somatostatin receptors (e.g., DOTATATE derivatives), as well as developing classes of radiotracers such as those targeting fibrinogen-activating protein (FAP) and carbonic anhydrase IX (CAIX), as well as newmeta-iodo-benzylguanidine (MIBG) derivatives. Most of those agents are still at the preclinical or early clinical stages of development, but as this is an emerging field, we aim to both outline current progress and suggest future directions.

摘要翻译： 

诊疗一体化，即利用诊断性放射性药物指导化学结构相同（或近乎相同）的治疗性放射性药物进行放射治疗，是核医学领域正在发展的新兴前沿方向。本文旨在系统综述诊疗一体化在头颈部领域的具体应用与发展动态，重点关注现有诊断用放射性示踪剂的治疗应用，包括靶向前列腺特异性膜抗原（PSMA）与生长抑素受体（如DOTATATE衍生物）的示踪剂；同时探讨处于研发阶段的示踪剂类别，如靶向纤维蛋白原激活蛋白（FAP）与碳酸酐酶IX（CAIX）的示踪剂，以及新型间碘苄胍（MIBG）衍生物。目前多数示踪剂尚处于临床前或早期临床研究阶段，鉴于该领域的快速发展态势，本文在梳理当前进展的同时，亦将展望未来发展方向。

原文链接：

A Look to the Future: Potential Theranostic Applications in Head and Neck Tumors